Case of high-risk epithelioid hemangioendothelioma of the neck.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 23019156.
- Also identified by DOI 10.1002/hed.23160.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Epithelioid hemangioendotheliomas (EHEs) of the head and neck region are uncommon malignant neoplasms that exhibit various biologic behaviors characteristic of both low- and high-grade malignancy. A subgroup of EHEs identified as "high-risk" EHEs because of their size and mitotic activity is associated with an unfavorable clinical course and poor prognosis. We describe the treatment of the first and, in terms of size, largest case of high-risk EHE arising from the neck. Despite wide excision, recurrence occurred 9 months after surgery, as had been expected. However, the tumor was found to express both vascular endothelial growth factor (VEGF) and VEGF receptor 2, indicating the potential of anti-VEGF therapy in the treatment of such cases. The finding that a high-risk EHE arising from the head and neck region is characterized by expression of VEGF and its receptor provides further support for the development of targeted molecular therapies.
Medical subject headings
- Head and Neck Neoplasms
- Hemangioendothelioma, Epithelioid
- Molecular Targeted Therapy
- Neoplasm Recurrence, Local
- Vascular Endothelial Growth Factor A
- Vascular Endothelial Growth Factor Receptor-2